Jasper Therapeutics, Inc. (JSPRW)

Market Cap	49.72M
Revenue (ttm)	n/a
Net Income (ttm)	-78.78M
Shares Out	15.02M
EPS (ttm)	-5.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0605 - 0.2526
Beta	2.73
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 5, 2025

About JSPRW

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Ronald Martell
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: JSPRW
• Website: https://jaspertx.com